Background
Methods
Patient population and diagnostic protocol
Lesion contouring
Lesion kinetics
Statistical analysis
Tumour/background ratio
Tumours and red marrow dosimetry
Results
Lesion kinetics
Local recurrences | Lymph node metastasis | Bone metastasis | p Local vs lymph node | p Local vs bone | p Lymph node vs Bone | |
---|---|---|---|---|---|---|
T1/2eff (T1/2biol) (h) | 8.8 ± 1.1 (28.7 ± 3.6) | 10.2 ± 1.7 (51.8 ± 8.6) | 9.0 ± 0.4 (30.9 ± 1.4) |
0.003
| 0.9 | 0.4 |
SUVmean at 1 h | 3.1 ± 1.1 | 5.2 ± 2.1 | 4.3 ± 0.9 |
< 0.001
|
0.003
| 0.8 |
SUVmax at 1 h | 4.7 ± 2.4 | 6.8 ± 4.3 | 6.8 ± 2.9 |
0.02
|
0.03
| 0.5 |
τ (h) | 1.1E-2 ± 2.4E-2 | 6.1E-3 ± 7.8E-3 | 6.4E-3 ± 1.0E-2 | 0.3 | 0.2 | 0.8 |
D/A (mGy/MBq) | 3.71E-2 ± 1.87E-2 | 9.65E-2 ± 5.95E-2 | 5.40E-2 ± 3.86E-2 |
< 0.001
| 0.1 | 0.6 |
Tumour/background ratio
Tumours and red marrow dosimetry
Organ | Absorbed organ dose per administered activity (mGy/MBq) |
---|---|
Adrenals | 2.54E-2 (± 6.60E-3) |
Brain | 1.04E-2 (± 3.95E-3) |
Breasts | 1.22E-2 (± 4.07E-3) |
Gallbladder wall | 7.82E-2 (± 2.99E-2) |
Lower larger intestine wall | 1.25E-2 (± 4.76E-3) |
Upper large intestine wall | 1.78E-2 (± 5.31E-3) |
Small intestine | 1.62E-2 (± 5.42E-3) |
Stomach wall | 1.70E-2 (± 5.48E-3) |
Heart wall | 1.80E-2 (± 5.30E-3) |
Kidneys | 1.39E-1 (± 3.72E-2) |
Liver | 2.71E-1 (± 3.37E-2) |
Lungs | 1.64E-2 (± 4.88E-3) |
Muscle | 1.34E-2 (± 4.51E-3) |
Pancreas | 8.39E-2 (± 4.03E-2) |
Red marrow | 2.26E-2 (± 9.04E-3) |
Osteogenic cells | 3.00E-2 (± 1.16E-2) |
Skin | 1.09E-2 (± 3.84E-3) |
Spleen | 3.63E-2 (± 1.37E-2) |
Testes | 1.10E-2 (± 4.14E-3) |
Thymus | 1.31E-2 (± 4.53E-3) |
Thyroid | 1.16E-2 (± 4.31E-3) |
Urinary bladder wall | 1.27E-2 (± 4.69E-3) |
Salivary glands | 3.70E-2 (± 3.70E-2) |
Total body | 2.09E-2 (± 5.61E-3) |
Effective dose ICRP 60 (mSv/MBq) | 3.10E-2 (± 8.07E-3) |
Effective dose ICRP 103 (mSv/MBq) | 2.91E-2 (± 7.83E-3) |